Part D Has Reduced Out-of-Pocket Rx Drug Costs in Diabetes

Share this content:
Part D Has Reduced Out-of-Pocket Rx Drug Costs in Diabetes
Part D Has Reduced Out-of-Pocket Rx Drug Costs in Diabetes

FRIDAY, Nov. 4, 2016 (HealthDay News) -- Medicare Part D has effectively reduced the out-of-pocket cost burden of prescription drugs for beneficiaries with diabetes, according to a study published online Nov. 1 in Diabetes Care.

Yoon Jeong Choi, from Seoul National University College of Nursing in South Korea, and colleagues used Medical Expenditure Panel Survey data for 2000 to 2011 to examine out-of-pocket costs for prescription drugs for 4,664 Medicare beneficiaries (≥65 years) versus 2,938 younger, non-Medicare adults (age 50 to 60 years) with diabetes.

The researchers observed an increase in Part D enrollment of Medicare beneficiaries with diabetes from 45.7 percent in 2006 to 52.4 percent in 2011. Following Part D implementation, out-of-pocket pharmacy costs decreased by 13.5 percent for all Medicare beneficiaries with diabetes compared with 2000 to 2005; Part D beneficiaries had 5.3 percent lower costs, on average, compared to those without Part D. For Medicare beneficiaries after Part D, out-of-pocket pharmacy costs decreased by 19.4 percent compared with a younger group with diabetes. From 2006 to 2011, there was a decrease in the proportion of Part D beneficiaries with diabetes who experienced the coverage gap (60.1 to 40.9 percent).

"Although Medicare Part D has been effective in reducing the out-of-pocket cost burden of prescription drugs, approximately two out of five Part D beneficiaries with diabetes experienced the coverage gap in 2011," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »